首页> 外文期刊>BMC Public Health >Digitally supported program for type 2 diabetes risk identification and risk reduction in real-world setting: protocol for the StopDia model and randomized controlled trial
【24h】

Digitally supported program for type 2 diabetes risk identification and risk reduction in real-world setting: protocol for the StopDia model and randomized controlled trial

机译:数字支持的2型糖尿病风险识别和风险减少的现实世界的计划:STOPDIA模型和随机对照试验的协议

获取原文
           

摘要

The StopDia study is based on the convincing scientific evidence that type 2 diabetes (T2D) and its comorbidities can be prevented by a healthy lifestyle. The need for additional research is based on the fact that the attempts to translate scientific evidence into actions in the real-world health care have not led to permanent and cost-effective models to prevent T2D. The specific aims of the StopDia study following the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework are to 1) improve the Reach of individuals at increased risk, 2) evaluate the Effectiveness and cost-effectiveness of the digital lifestyle intervention and the digital and face-to-face group lifestyle intervention in comparison to routine care in a randomized controlled trial (RCT), and 3) evaluate the Adoption and Implementation of the StopDia model by the participants and the health care organizations at society level. Finally, we will address the Maintenance of the lifestyle changes at participant level and that of the program at organisatory level after the RCT. The StopDia study is carried out in the primary health care system as part of the routine actions of three provinces in Finland, including Northern Savo, Southern Carelia, and P?ij?t-H?me. We estimate that one fifth of adults aged 18-70?years living in these areas are at increased risk of T2D. We recruit the participants using the StopDia Digital Screening Tool, including questions from the Finnish Diabetes Risk Score (FINDRISC). About 3000 individuals at increased risk of T2D (FINDRISC ≥12 or a history of gestational diabetes, impaired fasting glucose, or impaired glucose tolerance) participate in the one-year randomized controlled trial. We monitor lifestyle factors using the StopDia Digital Questionnaire and metabolism using laboratory tests performed as part of routine actions in the health care system. Sustainable and scalable models are needed to reach and identify individuals at increased risk of T2D and to deliver personalized and effective lifestyle interventions. With the StopDia study we aim to answer these challenges in a scientific project that is fully digitally integrated into the routine health care. ClinicalTials.gov . Identifier: NCT03156478 . Date of registration 17.5.2017.
机译:Stopdia研究基于令人信服的科学证据,即2型糖尿病(T2D)及其合并症可以通过健康的生活方式来预防其糖尿病。对额外研究的需求是基于,试图将科学证据转化为现实世界卫生保健中的行动,没有导致永久和经济效益的模型来预防T2D。在REACH,有效性,采用,实施和维护(重新瞄准)框架之后,STOPDIA研究的具体目标是提高风险增加,2)评估数字的有效性和成本效益在随机对照试验(RCT)中的常规护理(RCT)和3)中的生活方式干预和数字和面对面组的生活方式干预,以及参与者和社会医疗组织的通过和实施STAPDIA模型的采用和实施等级。最后,我们将解决在RCT之后的与参与者水平的生活方式变化的维护和程序的维护。 STOPDIA研究是在初级卫生保健系统中进行的,作为芬兰三个省份的常规行动的一部分,包括北方Savo,Carelia和P?IJ?T-H?我。我们估计,居住在这些地区的18-70岁的成年人的五分之一的成年人正在增加T2D的风险。我们使用Stopdia数字筛选工具招聘参与者,包括来自芬兰糖尿病风险评分(FindRisc)的问题。 T2D风险增加约3000人(FindRisc≥12或妊娠期糖尿病史,葡萄糖耐量受损的历史,葡萄糖耐受性受损)参与了一年的随机对照试验。我们使用作为医疗保健系统中的日常行动的一部分进行的实验室测试,监控使用Stopdia数字问卷和代谢的生活方式因素。需要可持续和可扩展的模型来达到和识别T2D的风险的增加,并提供个性化和有效的生活方式干预措施。随着Stopdia研究,我们的目标是在科学项目中回答这些挑战,这些挑战完全融入常规保健。 Clinicaltials.gov。标识符:NCT03156478。注册日期17.5.2017。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号